The use of immune globulin therapy appears to benefit children who experience acute heart failure caused by coronavirus disease 2019 (COVID-19)-related multisystem inflammatory syndrome, according to the findings of a case series recently published in Circulation.
Congestive heart failure (CHF) remains a leading cause of death and expenditure in the United States, affecting approximately 6.5 million people and costing more than $30 billion annually.1,2 Despite advances in medical therapy, the 5-year survival for patients with CHF is still approximately 50%.3 The prevalence of heart failure in the United States is expected…
More than 12-fold increase in DUA-IE hospitalizations and valve surgeries during 2007 to 2017
A calculator that estimates mortality for patients with unstable angina and non-ST elevation MI.
A calculator for determining Fract Excr of Urea (FEUr).
